Mechanism of selective motor neuronal death after exposure of spinal cord to glutamate: Involvement of glutamate‐induced nitric oxide in motor neuron toxicity and nonmotor neuron protection

DOI Web Site Web Site 被引用文献9件

抄録

<jats:title>Abstract</jats:title><jats:p>In this study, we analyzed the mechanism of selective motor neuronal death, a characteristic of amyotrophic lateral sclerosis, using embryonic rat spinal cord culture. When dissociated cultures were exposed to low‐level glutamate (Glu) coadministered with the Glu transporter inhibitor L‐<jats:italic>trans</jats:italic>‐pyrrolidine‐2,4‐decarboxylate (PDC) for 24 hours, motor neurons were selectively injured through <jats:italic>N</jats:italic>‐<jats:italic>methyl</jats:italic>‐D‐asparate (NMDA) and α‐amino‐3‐hydroxy‐5‐methylisoxazole‐4‐propionate (AMPA)/kainate receptors. Nitric oxide synthase (NOS) inhibitors attenuated this toxicity, and long‐acting nitric oxide (NO) donors damaged motor neurons selectively. Nonmotor neurons survived after exposure to low‐dose Glu/PDC, but Glu‐induced toxicity was potentiated by coadministration of an NO‐dependent guanylyl cyclase inhibitor. In addition, 8‐bromo‐cyclic GMP, a soluble cyclic GMP analogue, rescued nonmotor neurons, but not motor neurons, exposed to high‐dose Glu/PDC. Twenty‐four hours' incubation with PDC elevated the number of neuronal NOS‐immunoreactive neurons by about twofold compared with controls, and a double‐staining, study, using the motor neuron marker SMI32, revealed that most of them were nonmotor neurons. These findings suggest that selective motor neuronal death caused by chornic low‐level exposure to Glu is mediated by the formation of NO in nonmotor neurons, which inversely protects nonmotor neurons through the guanylyl cyclase‐cyclic GMP casade. Induction of neuronal NOS in nonmotor neurons might enhance both the toxicity of motor neurons and the protection of nonmotor neurons, which could explain the pathology of amyotrophic lateral sclerosis.</jats:p>

収録刊行物

被引用文献 (9)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ